Durable hearing gains from multicenter AAV1-hOTOF gene therapy for OTOF-related deafness
TL;DR
In a multicenter, single-arm trial across eight centers, 42 participants with autosomal recessive OTOF-related congenital deafness received AAV1-hOTOF at three doses. No dose-limiting toxicities were observed, and 90% of treated ears achieved hearing recovery with progressive, durable improvements in ABR/ASSR thresholds and speech perception up to 2.5 years. Younger participants showed greater gains, and baseline DPOAE strength and certain OTOF variants predicted better outcomes, supporting broad efficacy and safety of the therapy over up to 2.5 years.
- Multicentre gene therapy for OTOF -related deafness followed up to 2.5 years Nature
- Gene therapy for a rare type of deafness shows lasting results NPR
- 'Impressive' trial results for experimental gene therapy for deafness | STAT statnews.com
- Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind Live Science
- Hearing restoration lasts years after gene therapy for inherited deafness, new trial results show Medical Xpress
Want the full story? Read the original reporting
Read on Nature